Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.44 |
| ▸ | MAOA | P21397 | 6/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18884215 | 0.90 | MAOB (0.45) | MAOBMAOAPRKCIMEN1MAPK1 | |
| SCHEMBL17011806 | 0.84 | MAOA (0.56) | MAOBMAOAPRKCIMEN1MAPK1 | |
| SCHEMBL17332146 | 0.84 | MAOB (0.42) | MAOBMAOAPRKCIMEN1MAPK1 | |
| SCHEMBL17332134 | 0.84 | MAOA (0.42) | MAOBMAOAPRKCIMEN1MAPK1 | |
| SCHEMBL17332108 | 0.81 | MAOA (0.40) | MAOBMAOAPRKCIMEN1MAPK1 | |
| SCHEMBL17332094 | 0.81 | GRM5 (0.45) | MAOBMAOAPRKCIMEN1MAPK1 | |
| SCHEMBL19548369 | 0.81 | MAOB (0.46) | MAOBMAOAPRKCIMEN1MAPK1 | |
| SCHEMBL6121863 | 0.81 | MAOA (0.38) | MAOBMAOAPRKCIMEN1MAPK1 | |
| SCHEMBL19557218 | 0.81 | MAOA (0.40) | MAOBMAOAPRKCIMEN1MAPK1 | |
| SCHEMBL17332122 | 0.81 | SRD5A2 (0.49) | MAOBMAOAPRKCIMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452038-B1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE PREPARATION OF HEPATITIS C VIRUS (HCV) INHIBITORS | LAURUS LABS LTD (IN) | 2022-07-06 | — | — | EP | disclosed |
| US-11192875-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192875-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210139493-A1 | PREPARATION OF VELPATASVIR AND DERIVATIVE THEREOF | SHANGHAI FOREFRONT PHARMACEUTICAL CO LTD (CN) | 2021-05-13 | — | — | US | disclosed |
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| EP-3778606-A2 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778606-A2 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20200392100-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200392100-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013075029-A1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013075029-A1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2012068234-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012068234-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192875-B2 | Processes for preparing antiviral compounds | MAVS, EIF2AK2, SAMHD1 | MAOB 1117/4885MAOA 1588/4885PRKCI 2187/4885 |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | MAOB 3123/4885MAOA 3181/4885PRKCI 1749/4885 |
| US-20210139493-A1 | PREPARATION OF VELPATASVIR AND DERIVATIVE THEREOF | SAMHD1, TYMP, PNP | MAOB 2848/4885MAOA 3059/4885PRKCI 1321/4885 |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | MAOB 3123/4885MAOA 3181/4885PRKCI 1749/4885 |
| US-20200392100-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | MAOB 1117/4885MAOA 1588/4885PRKCI 2187/4885 |
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | MAOB 3123/4885MAOA 3181/4885PRKCI 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.